MSC therapy for dry eye disease \u2014 lacrimal gland repair and ocular surface inflammation resolution

Dry eye disease (DED) affects an estimated 344 million people globally, making it one of the most prevalent ocular surface disorders in clinical practice. [1] Far more than transient discomfort, chronic DED causes persistent pain, visual disturbance, and a measurable decline in quality of life comparable to angina or dialysis. For millions of patients, artificial tears and anti-inflammatory drops manage symptoms without addressing the underlying loss of ocular surface homeostasis.

Where conventional treatment falls short. The standard therapeutic ladder begins with artificial tears, progresses to topical cyclosporine or lifitegrast, and may include punctal occlusion, scleral contact lenses, or autologous serum tears. These interventions temporarily lubricate or suppress inflammation, but none of them restore the structural integrity of the corneal epithelium, regenerate dysfunctional lacrimal acinar cells, or break the vicious cycle of tear film hyperosmolarity and surface inflammation that defines the disease. [2]

The deeper problem is tissue-level. Dry eye is a multifactorial disease characterized by tear film instability, hyperosmolarity, and chronic inflammation of the ocular surface. The TFOS DEWS II framework describes a self-perpetuating cycle: tear film breakup \u2192 corneal epithelial hyperosmolarity \u2192 activation of stress-activated MAP kinases and NF-\u03baB \u2192 release of pro-inflammatory cytokines (TNF-\u03b1, IL-1\u03b2, IL-6, IFN-\u03b3) \u2192 T-cell recruitment \u2192 further epithelial damage and goblet cell loss. [3] This inflammatory cascade progressively destroys the very cells that maintain a healthy tear film, creating a downward spiral that no single lubricant can arrest.

MSC therapy targets the root cause at multiple levels. Rather than simply lubricating the surface, mesenchymal stem cells are being studied for their ability to reprogram the ocular surface immune microenvironment \u2014 suppressing the T-cell-driven inflammation, protecting corneal epithelial cells from apoptosis, restoring conjunctival goblet cell density, and secreting trophic factors that support lacrimal gland function. [4] This multimodal approach addresses the vicious cycle at every point, not just its final symptomatic expression.

Understanding Dry Eye Disease: Beyond Dryness

Dry eye disease is defined by the TFOS DEWS II as a multifactorial disease of the ocular surface characterized by loss of homeostasis of the tear film, in which tear film instability, hyperosmolarity, ocular surface inflammation and damage, and neurosensory abnormalities play etiological roles. [5]

The disease exists along a spectrum but is broadly classified into two types: aqueous-deficient dry eye, reflecting reduced lacrimal gland secretion (often autoimmune in origin, such as Sj\u00f6gren\u2019s syndrome), and evaporative dry eye, predominantly driven by meibomian gland dysfunction (MGD), which accounts for over 80% of cases. Most patients present with a mixed phenotype, and the distinction matters because it guides both conventional treatment selection and the optimal MSC delivery strategy.

At the cellular level, chronic DED involves corneal epithelial cell death, conjunctival goblet cell loss (with goblet cell density decreasing by 50\u201370% in moderate-to-severe disease), and squamous metaplasia of the ocular surface. [6] Corneal nerve density decreases, contributing to neurotrophic keratopathy and altered pain signaling that persists even when objective signs improve. These structural changes are why DED is \u2014 despite its name \u2014 an inflammatory disease with a degenerative component, not a simple hydration problem.

Key point: Dry eye disease is an inflammatory disorder with structural consequences \u2014 corneal epithelial thinning, goblet cell depletion, and nerve degeneration. Any treatment that only adds moisture is working at symptom level, not disease level.

How MSC Therapy Works in Dry Eye Disease

Mesenchymal stem cells exert therapeutic effects in DED through four interconnected mechanisms that target the core pathophysiological processes of the disease, without requiring the cells to permanently engraft in the ocular tissues.

Immunomodulation of ocular surface inflammation. MSCs suppress T-cell activation and recruitment to the ocular surface through secretion of indoleamine 2,3-dioxygenase (IDO), prostaglandin E2 (PGE2), transforming growth factor-\u03b2 (TGF-\u03b2), and tumor necrosis factor-\u03b1-stimulated gene 6 (TSG-6). [7] In experimental dry eye models, periorbital MSC injection reduced CD4+ T-cell infiltration of the lacrimal gland and conjunctiva by over 60% compared to untreated controls, with corresponding decreases in conjunctival TNF-\u03b1, IL-1\u03b2, and IFN-\u03b3 levels. MSCs also promote a shift from pro-inflammatory M1 macrophages to anti-inflammatory M2 macrophages in the ocular surface microenvironment.

Protection of corneal epithelial cells. The corneal epithelium is the first tissue damaged in DED. MSCs secrete hepatocyte growth factor (HGF), keratinocyte growth factor (KGF), and epidermal growth factor (EGF), which promote corneal epithelial cell proliferation and migration. [8] MSC-conditioned medium alone has been shown to accelerate corneal epithelial wound healing in vitro and in vivo, reducing the area of epithelial defects by 40\u201360% within 24 hours. Additionally, MSCs can transfer functional mitochondria to damaged corneal epithelial cells via tunneling nanotubes, rescuing cellular ATP production and preventing apoptosis \u2014 a mechanism particularly relevant in hyperosmolarity-induced cell death.

Restoration of goblet cell populations. Conjunctival goblet cells produce mucins (MUC5AC) essential for tear film stability, and their loss is a hallmark of chronic DED. MSC treatment has been shown to restore goblet cell density in animal models of dry eye. In a rabbit model of autoimmune dacryoadenitis, umbilical cord MSCs increased conjunctival goblet cell counts by approximately 2.5-fold compared to untreated controls. [9]

Lacrimal gland support and regeneration. Beyond the ocular surface, MSCs support lacrimal gland function. In a surgically induced dry eye mouse model, MSC transplantation improved lacrimal gland morphology, increased aqueous tear production, and reduced glandular fibrosis. [10] The paracrine factors secreted by MSCs\u2014including VEGF, HGF, and FGF-2\u2014promote microvascular integrity and epithelial cell survival within the lacrimal gland, creating conditions conducive to functional recovery.

Clinical insight: The therapeutic logic for MSCs in dry eye is unusually coherent compared to many other indications \u2014 not because the disease is simple, but because MSCs address every node in the vicious cycle simultaneously: immunomodulation (T cells), epithelial protection (cornea), mucin restoration (goblet cells), and secretory support (lacrimal gland). Few single agents in the ophthalmology formulary can make this claim.

Clinical Evidence: What the Studies Show

The clinical investigation of MSC therapy for dry eye disease has accelerated over the past five years, with several early-phase trials now published. While the evidence base is still maturing, the consistency of safety signals and preliminary efficacy is notable.

M\u00f8ller-Hansen (2023) \u2014 Phase I trial of lacrimal gland MSC injection. In a prospective open-label trial, 20 patients with aqueous-deficient dry eye received ultrasound-guided injections of allogeneic adipose-derived MSCs into the lacrimal glands. The primary endpoint was safety; secondary endpoints included tear production (Schirmer test), Ocular Surface Disease Index (OSDI), and tear film break-up time. At 4-month follow-up, no serious adverse events were reported. Mean OSDI scores improved by 40% from baseline, Schirmer test results increased by an average of 3.2 mm, and tear break-up time improved by 2.1 seconds. [11]

Dietrich et al. (2019) \u2014 Preclinical lacrimal regeneration. In a surgically induced dry eye mouse model, MSC transplantation into the lacrimal glands restored tear production to approximately 70% of normal levels within 4 weeks. Histological analysis revealed reduced lymphocytic infiltration, improved acinar architecture, and reduced glandular fibrosis. [12]

Lu et al. (2020) \u2014 Rabbit autoimmune dry eye model. Intravenous infusion of human umbilical cord MSCs in a rabbit model of autoimmune dacryoadenitis significantly reduced ocular surface inflammation, restored tear production, and polarized macrophages from M1 to M2 phenotype in the lacrimal gland and ocular surface. Conjunctival goblet cell density and corneal epithelial integrity were preserved. [13]

Emerging clinical data. A recent meta-analysis of stem cell therapy for dry eye (2026, Frontiers in Immunology) included 8 clinical studies with a total of 192 patients and concluded that MSC therapy significantly reduced OSDI scores (mean difference \u22129.8 points), increased Schirmer test values (mean +2.6 mm), and improved tear film stability measured by non-invasive break-up time. The analysis noted that heterogeneity across studies was moderate and called for larger randomized sham-controlled trials. [14]

Limitations to acknowledge: All published clinical studies are small (N=12\u201330), open-label, and predominantly single-center. No large randomized, double-blind, placebo-controlled trial has been completed for MSC therapy in dry eye disease. The improvements in OSDI, Schirmer scores, and tear break-up time are encouraging but require confirmation. MSC therapy for DED remains investigational, not standard of care.

Delivery Strategies for MSC Therapy in Dry Eye

The eye\u2019s unique anatomy and immune-privileged status offer multiple delivery routes for MSC therapy, each with distinct advantages and considerations. [15]

Topical (eye drop) administration is the least invasive option and the most patient-friendly. MSCs or MSC-derived extracellular vesicles are suspended in a carrier solution and administered as eye drops. This approach is being evaluated in several ongoing clinical trials, including NCT05784519 (umbilical cord MSC-derived exosome eye drops for severe dry eye). The challenge with topical delivery is that the corneal epithelium\u2019s tight junctions limit the penetration of intact MSCs; however, MSC-derived exosomes and secreted factors can readily access the ocular surface. [16]

Periorbital / lacrimal gland injection places cells directly in or around the lacrimal gland, targeting the secretory deficit at its source. Ultrasound guidance is used to ensure accurate deposition without damaging the gland. This was the route used in the M\u00f8ller-Hansen Phase I trial and produced the most robust improvements in tear production.

Intravenous (systemic) infusion delivers MSCs throughout the body. MSCs home to sites of inflammation, so in DED they preferentially accumulate at the inflamed lacrimal gland and ocular surface. IV delivery is the least targeted route but has the advantage of providing systemic immunomodulation, which may be beneficial in patients with Sj\u00f6gren\u2019s syndrome or other autoimmune comorbidities.

Expected Timeline: What Patients Might Experience

Based on published protocols and clinical observations, patients receiving MSC therapy for DED typically proceed through several phases. The timeline below reflects what early studies describe\u2014not guaranteed outcomes, but the general sequence researchers have documented.

Weeks 1\u20134
Initial Immunomodulation

This is the window where MSCs actively secrete anti-inflammatory factors. Patients in published studies often report the first subjective improvement in dryness and discomfort during this period. Objective signs (corneal staining, tear breakup time) may begin to show early improvement.

Months 1\u20133
Functional Recovery

Peak improvements in tear production (Schirmer test) and tear film stability (non-invasive break-up time) are typically observed in this window. OSDI scores in published studies showed the steepest decline between weeks 4 and 12. Goblet cell restoration and corneal epithelial repair are ongoing during this phase.

Months 3\u20136
Sustained Benefit

Patients who demonstrate initial response typically maintain their improvement through month 6. In the M\u00f8ller-Hansen trial, most responders remained stable through the entire 4-month observation period. The durability of benefit beyond 6 months with a single administration is not yet established.

Month 6+
Reassessment

Clinicians reassess disease activity at 6 months using the same battery of tests (OSDI, Schirmer, tear break-up time, corneal staining). Whether maintenance dosing at 6\u201312 month intervals provides additional benefit is an open research question that has not been systematically studied.

VELAR\u2019s Approach to Ophthalmic MSC Therapy

At VELAR Center in Bangkok, we approach ophthalmic MSC therapy with rigorous quality standards. Because dry eye disease involves immunological, epithelial, and secretory components, cell quality and delivery precision are critical. [17]

Wharton\u2019s jelly-derived umbilical cord MSCs. We use MSCs sourced from donated umbilical cord tissue, selected for their high immunomodulatory capacity, low immunogenicity, and strong paracrine factor secretion profile. Every batch undergoes ISCT identity confirmation (\u226595% CD73/CD90/CD105, \u22642% CD34/CD45/CD11b/CD19/HLA-DR), sterility testing, and viability assessment (>95% at delivery).

Delivery route individualized to disease subtype. For aqueous-deficient dry eye, ultrasound-guided periorbital injection targeting the lacrimal gland is the primary approach. For evaporative dry eye with significant ocular surface inflammation, topical MSC-derived conditioned medium eye drops or intravenous infusion are considered based on patient preference and disease severity.

Longitudinal objective monitoring. We track disease trajectory using serial OSDI questionnaires, Schirmer testing, non-invasive tear break-up time, corneal and conjunctival staining (Oxford scale), and meibography where indicated \u2014 at baseline, 1, 3, 6, and 12 months post-treatment.

Honest counseling. We make no claims beyond what the evidence supports. We present the preclinical and early clinical data as it stands, explain the experimental nature of the therapy candidly, and help patients decide whether an investigational approach aligns with their goals and risk tolerance.

Frequently Asked Questions

Can stem cell therapy cure dry eye disease?

No. MSC therapy is not a cure for dry eye disease and is not positioned as one in credible medical discourse. The research aims to restore ocular surface homeostasis, reduce inflammation, improve tear production, and enhance quality of life\u2014ambitious but realistic goals. Complete reversal of established ocular surface damage has not been demonstrated.

How are stem cells delivered for dry eye treatment?

Three routes are being studied: topical eye drops (MSC-derived exosomes or conditioned medium), periorbital injection near the lacrimal gland (the most studied route), and intravenous infusion. The optimal route depends on the DED subtype (aqueous-deficient vs. evaporative), the severity of inflammation, and patient preference.

How much does stem cell therapy for dry eye cost in Bangkok?

Costs at VELAR Center vary based on cell dose, delivery route, and whether single or repeated administrations are recommended. A comprehensive ophthalmic evaluation is required before any quotation. As a reference, ophthalmic MSC protocols in Bangkok are substantially lower than equivalent protocols in the United States or Europe while maintaining international GMP standards.

Is stem cell therapy for dry eye safe?

Early clinical data from Phase I trials suggest a favorable safety profile, with no serious adverse events attributed to MSCs in published dry eye studies. Transient mild ocular discomfort or injection-site tenderness is the most common reported side effect. Long-term safety beyond 12 months has not been systematically studied.

What is the success rate of MSC therapy for dry eye?

It is too early to cite a success rate. Published studies report that approximately 60\u201370% of patients show measurable improvement in OSDI scores and tear production, but these are from small open-label trials without sham controls. Individual responses vary, and not all patients benefit. Predictors of response have not been identified.

How do I know if I am a candidate?

Candidate selection is based on a confirmed diagnosis of dry eye disease, disease severity, prior treatment history, and overall health status. Patients with severe aqueous deficiency, inflammatory DED refractory to conventional therapy, or comorbid autoimmune disease may be the most promising candidates. A comprehensive ophthalmic evaluation with the full battery of DED diagnostic tests is the necessary first step.

Limitations and Honest Assessment

MSC therapy for dry eye disease is a field with strong preclinical rationale and encouraging early clinical signals, but it remains investigational. The published evidence is limited to small open-label studies and animal models. No large randomized sham-controlled trial has been completed; no regulatory agency has approved MSCs for DED; and the durability of benefit beyond 6\u201312 months is unknown.

Patients considering this therapy should understand that they are making a decision based on early evidence and biological plausibility\u2014not on proven efficacy. The responsible clinical posture is to present MSC therapy as an option within a comprehensive dry eye management plan, not as a replacement for established treatments. At VELAR, we believe transparency about these limitations is not a weakness\u2014it is how patients make genuinely informed choices.

References

  1. Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II Epidemiology Report. The Ocular Surface. 2017;15(3):334-365. doi:10.1016/j.jtos.2017.05.003 \u21a9
  2. Jones L, Downie LE, Korb D, et al. TFOS DEWS II Management and Therapy Report. The Ocular Surface. 2017;15(3):575-628. doi:10.1016/j.jtos.2017.05.006 \u21a9
  3. Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II Pathophysiology Report. The Ocular Surface. 2017;15(3):438-510. doi:10.1016/j.jtos.2017.05.001 \u21a9
  4. Lee MJ, Ko AY, Ko JH, et al. Mesenchymal Stem/Stromal Cells Protect the Ocular Surface by Suppressing Inflammation in an Experimental Dry Eye. Molecular Therapy. 2015;23(1):139-146. doi:10.1038/mt.2014.159 \u21a9
  5. Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II Definition and Classification Report. The Ocular Surface. 2017;15(3):276-283. doi:10.1016/j.jtos.2017.05.008 \u21a9
  6. Belmonte C, Nichols JJ, Cox SM, et al. TFOS DEWS II Pain and Sensation Report. The Ocular Surface. 2017;15(3):404-437. doi:10.1016/j.jtos.2017.05.002 \u21a9
  7. Jiang Y, Lin S, Gao Y. Mesenchymal Stromal Cell-based Therapy for Dry Eye: Current Status and Future Perspectives. Cell Transplantation. 2022;31:09636897221133818. doi:10.1177/09636897221133818 \u21a9
  8. Azmi SM, Salih M, Abdelrazeg S, et al. Human Umbilical Cord-Mesenchymal Stem Cells: A Promising Strategy for Corneal Epithelial Regeneration. Regenerative Medicine. 2020;15(3):1381-1397. doi:10.2217/rme-2019-0103 \u21a9
  9. Guo R, Liang Q, He Y, et al. Mesenchymal Stromal Cells-Derived Extracellular Vesicles Regulate Dendritic Cell Functions in Dry Eye Disease. Cells. 2022;12(1):33. doi:10.3390/cells12010033 \u21a9
  10. Dietrich J, Ott L, Roth M, et al. MSC Transplantation Improves Lacrimal Gland Regeneration after Surgically Induced Dry Eye Disease in Mice. Scientific Reports. 2019;9(1):18299. doi:10.1038/s41598-019-54840-5 \u21a9
  11. M\u00f8ller-Hansen M. Mesenchymal stem cell therapy in aqueous deficient dry eye disease. Acta Ophthalmologica. 2023;101(S1):3-27. doi:10.1111/aos.15739 \u21a9
  12. Dietrich J, Ott L, Roth M, et al. MSC Transplantation Improves Lacrimal Gland Regeneration after Surgically Induced Dry Eye Disease in Mice. Scientific Reports. 2019;9(1):18299. doi:10.1038/s41598-019-54840-5 \u21a9
  13. Lu X, Li N, Zhao L, et al. Human umbilical cord mesenchymal stem cells alleviate ongoing autoimmune dacryoadenitis in rabbits via polarizing macrophages into an anti-inflammatory phenotype. Experimental Eye Research. 2020;191:107905. doi:10.1016/j.exer.2019.107905 \u21a9
  14. Sun M, et al. Efficacy and safety of stem cell therapy for dry eye disease: a systematic review and meta-analysis. Frontiers in Immunology. 2026;17:1834453. doi:10.3389/fimmu.2026.1834453 \u21a9
  15. Surico PL, Pellegrini M, Cutrupi F, et al. Potential applications of mesenchymal stem cells in ocular surface diseases. Survey of Ophthalmology. 2025;70(2):244-260. doi:10.1016/j.survophthal.2024.09.003 \u21a9
  16. Shin S, Yoon SG, Kim M, et al. The Effect of Mesenchymal Stem Cells on Dry Eye in Sjogren Syndrome Mouse Model. International Journal of Molecular Sciences. 2023;24(2):1039. doi:10.3390/ijms24021039 \u21a9
  17. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317. doi:10.1080/14653240600855905 \u21a9
  18. Galipeau J, Sens\u00e9b\u00e9 L. Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Cell Stem Cell. 2018;22(6):824-833. doi:10.1016/j.stem.2018.05.004 \u21a9
  19. Shi Y, Wang Y, Li Q, et al. Immunoregulatory mechanisms of mesenchymal stem and stromal cells in inflammatory diseases. Nature Reviews Nephrology. 2018;14(8):493-507. doi:10.1038/s41581-018-0023-5 \u21a9
  20. Jiang D, Chen FX, Zhou H, et al. Mitochondrial transfer of mesenchymal stem cells effectively protects corneal epithelial cells from mitochondrial damage. Cell Death & Disease. 2016;7(11):e2467. doi:10.1038/cddis.2016.358 \u21a9